Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290624 | 1.00 | KDM4E (0.43) | KDM4ECYP1A2KMT2AMEN1CYP2C19 | |
| SCHEMBL34463743 | 1.00 | KDM4E (0.43) | KDM4ECYP1A2KMT2AMEN1CYP2C19 | |
| SCHEMBL13339371 | 1.00 | KDM4E (0.43) | KDM4ECYP1A2KMT2AMEN1CYP2C19 | |
| SCHEMBL27743245 | 0.84 | KMT2A (0.43) | KDM4ECYP1A2KMT2AMEN1GBA1 | |
| SCHEMBL15583053 | 0.81 | KMT2A (0.49) | KDM4ECYP1A2KMT2AMEN1GBA1 | |
| SCHEMBL901166 | 0.81 | KMT2A (0.50) | KDM4ECYP1A2KMT2AMEN1GBA1 | |
| SCHEMBL5376000 | 0.80 | MEN1 (0.48) | KDM4ECYP1A2KMT2AMEN1CYP2C19 | |
| SCHEMBL4367349 | 0.80 | MEN1 (0.58) | KDM4ECYP1A2KMT2AMEN1CYP2C19 | |
| SCHEMBL13367174 | 0.77 | GBA1 (0.42) | KDM4ECYP1A2KMT2AMEN1GBA1 | |
| SCHEMBL2562377 | 0.76 | CYP1A2 (0.65) | KDM4ECYP1A2KMT2AMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111535-B2 | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | QIAGEN GMBH (DE) | 2021-09-07 | — | — | US | claimed |
| US-20170081719-A1 | PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME | QIAGEN GMBH (DE) | 2017-03-23 | — | — | US | claimed |
| CN-1833034-B | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | EXIQON AS | 2014-04-16 | — | — | CN | claimed |
| CN-101090979-A | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | EXIQON AS (DK) | 2007-12-19 | — | — | CN | claimed |
| CN-1833034-A | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | EXIQON AS (DK) | 2006-09-13 | — | — | CN | claimed |
| US-20060166238-A1 | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | EXIQON A/S (DK) | 2006-07-27 | — | — | US | claimed |
| US-7060809-B2 | LNA compositions and uses thereof | EXIQON A/S (DE) | 2006-06-13 | — | — | US | claimed |
| US-20050089889-A1 | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | EXIQON A/S (DK) | 2005-04-28 | — | — | US | claimed |
| EP-1446412-A2 | NOVEL LNA COMPOSITIONS AND USES THEREOF | Exiqon A/S (DK) | 2004-08-18 | — | — | EP | claimed |
| US-20030224377-A1 | Novel LNA compositions and uses thereof | QIAGEN GMBH (DE) | 2003-12-04 | — | — | US | claimed |
| WO-2003020739-A2 | NOVEL LNA COMPOSITIONS AND USES THEREOF | EXIQON A/S (DK) | 2003-03-13 | — | — | WO | claimed |
| US-20260125680-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION | MASSACHUSETTS GEN HOSPITAL (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3846824-B1 | COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION | MASSACHUSETTS GEN HOSPITAL (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20240240181-A1 | NEUROPROTECTIVE MOLECULES AND METHODS OF TREATING NEUROLOGICAL DISORDERS AND INDUCING STRESS GRANULES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20230414790-A1 | miRNA PROFILING COMPOSITIONS AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2003052133-A2 | OLIGONUCLEOTIDE ANALOGUES COMPRISING INTERCALATOR PSEUDONUCLEOTIDES | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003052134-A2 | OLIGONUCLEOTIDES COMPRISING INTERCALATOR PSEUDONUCLEOTIDE(S) FOR DETECTION OF NUCLEIC ACIDS AND MUTANTS HEREOF | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051901-A2 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003039523-A2 | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES | EXIQON A/S (DK) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003020739-A2 | NOVEL LNA COMPOSITIONS AND USES THEREOF | EXIQON A/S (DK) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125680-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CHECKPOINT INHIBITION | PDCD1LG2, CD274, PDCD1 | KDM4E 598/4885CYP1A2 4862/4885KMT2A 961/4885 |
| US-20050089889-A1 | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | RNGTT, POLRMT, DNTT | KDM4E 4682/4885CYP1A2 3647/4885KMT2A 1827/4885 |
| US-20030224377-A1 | Novel LNA compositions and uses thereof | RNGTT, NCL, NSUN2 | KDM4E 4632/4885CYP1A2 4884/4885KMT2A 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.